113 citations
,
August 2016 in “Mycopathologia” New topical antifungals and delivery systems are improving treatment for fungal skin infections, but patient education and prevention are key.
October 2021 in “Dermatology Reports” Tofacitinib, a hair regrowth treatment, may worsen acne.
1 citations
,
June 1999 in “American Journal of Contact Dermatitis” Tazarotene gel is more effective for acne than tretinoin and works as well as adapalene.
5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
January 2024 in “Faculty of 1000 Research Ltd” Tazarotene gel may be more effective for acne than adapalene gel.
4 citations
,
August 2023 in “Varna Medical Forum” TECAR therapy helps with pain relief, reduces inflammation, relaxes muscles, heals tissues, and is safe and effective for many conditions.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
December 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
May 2026 in “Indian Journal of Dermatology” Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
January 2015 in “Journal of evolution of medical and dental sciences” Topical tacrolimus is effective and safe for treating alopecia areata.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
December 2023 in “Acta dermato-venereologica” Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.